News

Opdivo is a programed death-1 (PD-1) immune checkpoint inhibitor that has received approval from the FDA as a monotherapy in two cancer indications. The sBLA is based on

Kybella is a cytolytic drug, which when injected into the fat under the chin destroys the cell membrane. When injected into submental fat, the drug works by destroying

Brilinta is a direct-acting, selective and reversibly binding P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs) and it works by inhibiting platelet activation. The sNDA is

Earlier this month, Mylan offered to buy Perrigo in a deal valued at nearly $29bn, under which Perrigo shareholders would receive $205 per share. However, board of directors

The company’s all-natural Tapout product line includes their high potency Omega 3 Fish Oil supplements and all-natural, gluten free, protein shakes. The deal is part of Axxess’s aim

The company believes that the claims made in this litigation were without merit, and it did not admit liability. Currently, the diabetes drug will be available as a

IC, commonly referred to as painful bladder syndrome (PBS), is a chronic disease characterized by bladder pressure, bladder pain, urinary urgency and/or urinary frequency. It affects an estimated

The company said that this first-in-human trial is currently open at Horizon Oncology in Lafayette, Indiana, Sarah Cannon Research Institute in Nashville, Tennessee, the John Theurer Cancer Center

Navidea previously announced its intention to decrease its R&D expenses by divesting its non-core neuroimaging assets. This agreement follows through on the Company’s commitment to decrease cash burn